Insomnia Pharmacological Treatment Markets: Over-the-Counter Sleep Aids and Prescription Sleep Aids – Global Forecast to 2026 – Cumulative Impact of COVID-19 –

Insomnia Pharmacological Treatment Markets: Over-the-Counter Sleep Aids and Prescription Sleep Aids – Global Forecast to 2026 – Cumulative Impact of COVID-19 –

Insomnia Pharmacological Treatment Markets: Over-the-Counter Sleep Aids and Prescription Sleep Aids – Global Forecast to 2026 – Cumulative Impact of COVID-19 –

DUBLIN–(BUSINESS WIRE)–The “Insomnia Pharmacological Treatment Market Research Report by Treatment (Over-the-Counter Sleep Aids and Prescription Sleep Aids), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2026 – Cumulative Impact of COVID-19” report has been added to’s offering.

The Global Insomnia Pharmacological Treatment Market size was estimated at USD 7,530.46 Million in 2020 and expected to reach USD 7,985.76 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.38% to reach USD 10,916.69 Million by 2026.

In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Cumulative Impact of COVID-19:

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Insomnia Pharmacological Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.

Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

3.1. Introduction

3.2. Market Outlook

3.3. Treatment Outlook

3.4. Region Outlook

3.5. Competitor Outlook

4. Market Overview

4.1. Introduction

4.2. Cumulative Impact of COVID-19

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers Increasing stress level and physical disorders Prevalence of chronic insomnia in adult patients Rising awareness among patient and increasing visits to doctor regarding to insomnia

5.1.2. Restraints Side effects associated with drugs

5.1.3. Opportunities Development of novel products Increase in penetration of new pharmaceuticals in developing areas

5.1.4. Challenges Individual level stigma about insomnia in some patients

5.2. Porters Five Forces Analysis

6. Insomnia Pharmacological Treatment Market, by Treatment

6.1. Introduction

6.2. Over-the-Counter Sleep Aids

6.2.1. Antihistamines

6.2.2. Melatonin

6.2.3. Valerian Roots

6.3. Prescription Sleep Aids

6.3.1. Benzodiazepines

6.3.2. Melatonin Receptor Antagonists

6.3.3. Non-benzodiazepines Eszopiclone Zaleplon Zolpidem

6.3.4. Orexin Antagonists

Companies Mentioned

  • Aa Pharma Inc
  • Actavis Totowa LLC
  • Altimed Pharma Inc.
  • Amneal Pharmaceuticals NY LLC
  • Direct_Rx
  • Ebb Therapeutics
  • Eisai Co., Ltd.
  • Foxland Pharmaceuticals, Inc.
  • Fresenius Kabi USA, LLC
  • Hospira, Inc.
  • Ingenus Pharmaceuticals, LLC
  • Meda Consumer Healthcare, Inc
  • MEDA Pharmaceuticals
  • MedPointe Pharmaceuticals
  • Merck & Co., Inc.
  • Micro Labs Limited
  • Mylan N.V.
  • Paratek Pharmaceuticals, Inc.
  • Pernix Therapeutics
  • Pfizer Inc.
  • Pro Doc Limitee
  • Purdue Pharmaceuticals L.P.
  • Remedy Repack
  • Sanofi S.A.
  • Sivem Pharmaceuticals Ulc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceuticals Company Ltd.
  • TriVue Pharmaceuticals, Inc.
  • Vanda Pharmaceuticals
  • Winthrop U.S.

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900